Study compares three weekly regimens of chemotherapy for lung cancer

July 31, 2003

PITTSBURGH, July 31 - According to findings published in the Aug. 1 issue of the Journal of Clinical Oncology, weekly regimens of paclitaxel in combination with full doses of carboplatin is reasonably well tolerated and the efficacy results appear promising. The study, led by Chandra P. Belani, M.D., professor of medicine, University of Pittsburgh and co-director, Lung Cancer Program, University of Pittsburgh Cancer Institute (UPCI), compared three regimens of weekly paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer (NSCLC) and found that higher weekly doses of paclitaxel in combination therapy for lung cancer did not result in an added benefit for patients and caused a higher incidence of adverse side effects.

"Our study demonstrates that both agents can be administered with ease and without substantial toxicity when weekly paclitaxel is combined with full doses of carboplatin administered on day one of each cycle with few side effects," said Dr. Belani. "Administration of a higher weekly dose of paclitaxel did not improve survival and was more likely to cause toxic effects from treatment. This is a major concern for lung cancer patients with advanced disease given that the primary goal of therapy is to improve survival, reduce symptoms and to improve the patient's quality of life."

The purpose of the study was to explore the efficacy and safety of three regimens of weekly paclitaxel plus carboplatin. The study included 401 patients with stage III and IV NSCLC from 47 community and academic sites in the United States. Patients were randomly assigned into one of three groups. The first group received 100mg/m2 of paclitaxel weekly for three of four weeks with carboplatin on day one. The second group received 100mg/m2 of paciltaxel and carboplatin weekly for three of four weeks. The third and final group received 150mg/m2 to 100mg/m2 of paclitaxel and carboplatin weekly for six of eight weeks.

Results indicated that group one was associated with overall improved efficacy and the most favorable toxicity profile. Patients assigned to this group demonstrated a response rate of 32 percent and a median survival time of 49 weeks, with a one-year survival rate of 47 percent, while patients in group two had a response rate of 24 percent and a median survival time of 31 weeks. Patients in group three had a response rate of 18 percent and a median survival time of 40 weeks.

"These results are encouraging," said Dr. Belani and will lead to increasing use of this regimen in advanced NSCLC. According to Dr. Belani, a phase III randomized study is underway to compare this schedule with the standard three week regimen of paclitaxel and carboplatin.

Lung cancer will be newly diagnosed in over 170,000 people in the United States in 2003. Non-small cell lung cancer is the most common type of lung cancer, accounting for nearly 80 percent of lung cancers.
-end-
For more information on lung cancer, please visit www.upmccancercenters.com.

CONTACT:
Clare Collins
Jocelyn Uhl
PHONE: 412-647-3555
FAX: 412-624-3184
E-MAIL:
CollCX@upmc.edu
UhlJH@upmc.edu

University of Pittsburgh Medical Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.